Intellia Therapeutics Inc
Research Intellia Therapeutics Inc (NTLA) on Bullrun: market cap USD 1.89B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNTLA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.89B
- Financial periodQ2 2026
- RevenueUSD 7.66M
- Net income-USD 106.63M
- Free cash flow-USD 84.92M
Valuation Snapshot
latest market cap is USD 1.89B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 67.67M | -USD 412.69M | -USD 395.87M | n/a | -3.81 | USD 155.46M | USD 93.33M | USD 671.39M |
| FY2024 | USD 57.88M | -USD 519.02M | -USD 354.66M | n/a | -5.25 | USD 189.18M | USD 210.20M | USD 871.96M |
| FY2023 | USD 36.28M | -USD 481.19M | -USD 408.07M | n/a | -5.42 | USD 226.75M | USD 115.35M | USD 1.05B |
| FY2022 | USD 52.12M | -USD 474.19M | -USD 346.85M | n/a | -6.16 | USD 523.51M | USD 69.57M | USD 1.24B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.89B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.05B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.19B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.73B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.01B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 8.81B | n/a | n/a | n/a |
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Intellia Therapeutics Inc's market cap?
Intellia Therapeutics Inc's market capitalization is USD 1.89B.
What does Intellia Therapeutics Inc do?
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases.